Supplements
curcumin improves depression symptoms
In plain terms: Can turmeric help with depression?
Part of: 🧪 turmeric & curcumin
Maybe, as an add-on to antidepressants. A couple of meta-analyses show a benefit, but the trials are small, overlapping, and prone to publication bias — promising, not established.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
A couple of meta-analyses find curcumin reduces depressive symptoms — but the underlying trials are small, short, heavily overlapping, mostly tested it as an add-on to antidepressants, and carry a real risk of publication bias. Promising as an adjunct, not an established antidepressant.
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| She RF, Zhang Q, Zhao FF, Yang K, Chen Q, Yang YF, Li HJ, Li XH, Li XT 2026 · Chinese journal of integrative medicine | animal | supports | low | Rotenone-induced Parkinson's rat model (n=14/group); intranasal curcumin (2.5-10 mg/kg/d) reduced anxio-depressive-like behaviors (FST/TST/open field) vs vehicle, comparable to fluoxetine, via NF-κB/NLRP3 pathway modulation. |
| Kukushkina A, Rogovskii V, Zhilenkova O, Sadekov T, Melnikov M, Boyko A 2026 · Pharmaceutics | RCT | tested-null | low | 60 MS patients on IFN-β randomized to add-on micellar curcumin vs IFN-β alone for 6 months; reported 'a positive effect on depression (p=0.05)' alongside relapse-rate benefits, but this was a secondary/exploratory endpoint in a small pilot |
| Osei-Bonsu GA, Dimick MK, Kennedy KG, Barton JS, Sultan AA, Young LT, Andreazza AC, Goldstein BI 2026 · Journal of child and adolescent psychopharmacology | observational | supports | low | Open-label, uncontrolled pilot trial (n=6 youth) of adjunctive curcumin (up to 1000mg BID) for treatment-resistant bipolar depression over 8 weeks; significant reduction in CGI depression/illness severity, with reduction in CDRS-R scores co |
| Sarris J, Ravindran A, Yatham LN, Marx W, Rucklidge JJ, McIntyre RS, Akhondzadeh S, Benedetti F, Caneo C, Cramer H, Cribb L, de Manincor M, Dean O, Deslandes AC, Freeman MP, Gangadhar B, Harvey BH, Kasper S, Lake J, Lopresti A, Lu L, Metri NJ, Mischoulon D, Ng CH, Nishi D, Rahimi R, Seedat S, Sinclair J, Su KP, Zhang ZJ, Berk M 2022 · World J Biol Psychiatry | observational | mixed | low | Clinician nutraceutical guidelines: curcumin has preliminary/adjunctive evidence in depression, not first-line. |
| Singh A, Sharma N 2026 · Natural product research | observational | supports | low | Narrative review of curcumin's neuroinflammatory mechanisms in depression (NLRP3 inhibition, kynurenine pathway, inflammatory marker reduction); asserts 'evidence from clinical trials and meta-analyses suggests curcumin can significantly al |
| Zhang K, Zhao Y, Chen X, Li Y, Lan T, Chang M, Wang W, Wang C, Zhuang X, Zhang B, Yu S 2025 · Redox biology | animal | supports | low | Chronic corticosterone-induced depression/anxiety model in mice; curcumin treatment ameliorated depressive/anxiety-like behaviors and oxidative stress/neuroinflammation via p53-DDIT4-NF-κB pathway (mechanistic pharmacological rescue/challen |
| Ng QX, Koh SSH, Chan HW, Ho CYX 2017 · J Am Med Dir Assoc | meta-analysis | supports | low | Meta-analysis: curcumin showed clinically significant antidepressant efficacy vs placebo. |
| Yuan J, Pi C, Shen H, Zhou B, Wei Y, Dechsupa N, Zhao L 2025 · Frontiers in pharmacology | meta-analysis | supports | moderate | Systematic review/meta-analysis of 15 RCTs (n=1123 adults) with chronic diseases; curcumin significantly reduced depressive symptoms (SMD -0.65, 95% CI -1.16 to -0.13, I²=93%) and anxiety (SMD -0.22), but authors flag considerable heterogen |
| Fusar-Poli L, Vozza L, Gabbiadini A, Vanella A, Concas I, Tinacci S, Petralia A, Signorelli MS, Aguglia E 2020 · Crit Rev Food Sci Nutr | meta-analysis | supports | low | Meta-analysis: curcumin significantly reduced depressive symptoms across randomized trials. |
| Chen T, Liu X, Li D, Cheng Z, Zheng X, Yu Z 2026 · International journal of nanomedicine | animal | supports | low | In vitro (BV2 cells) and in vivo CUMS mouse model; curcumin-loaded lipid nanoparticles (CNP) alleviated depressive-like behaviors more effectively than free curcumin, with enhanced anti-inflammatory/antioxidant effects. |
| Wang Z, Zhang Q, Huang H, Liu Z 2021 · J Affect Disord | meta-analysis | mixed | moderate | SR+meta-analysis: antidepressant signal present but evidence limited by small, heterogeneous, potentially biased trials. |
| Baune BT, Patel MM, Patel MV, Gupta SN 2026 · Journal of integrative and complementary medicine | meta-analysis | supports | low | Node-resolved systematic review/meta-analysis of Ayurvedic herbal products (49 controlled human reports, 20 nodes); meta-analysis was feasible for curcumin vs placebo on depression severity as one of three primary strata, showing a 'potenti |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.